Recordati Group Sees Impressive Growth in Financial Performance
The Recordati Group is proud to announce significant achievements in its financial results for the first half of 2025. The company has reported solid consolidated net revenue of €1,323.8 million, marking an impressive growth of 11.7%. Even more encouraging is the 7.8% increase on a like-for-like basis, reflecting the organization’s commitment to delivering quality healthcare products and services.
EBITDA and Income Growth
This period also indicates a robust EBITDA of €496.3 million, representing a 9.6% increase compared to the previous year. The EBITDA margin reached an impressive 37.5%, showcasing operational efficiency amidst expanding revenues. The adjusted net income experienced notable growth, rising to €327.8 million, reflecting an 8.9% increase year-on-year.
Free Cash Flow and Debt Management
Free cash flow has shown resilience, recorded at €256.8 million, indicating stability in financial operations. As of June 30, 2025, net debt was reported at €2,127.1 million, which translates into a leverage of just below 2.3x EBITDA pro-forma. This demonstrates a balanced approach to managing debt while driving growth.
Licensing Collaborations and Corporate Developments
A significant highlight for Recordati is its licensing and supply agreement with Amarin to commercialize the cardiovascular medicine, Vazkepa, across Europe. This partnership not only enhances the company’s portfolio but also strengthens its position in the fast-growing cardiovascular therapeutic area.
Steady Growth in Specialty & Primary Care and Rare Diseases
Recordati realized that the momentum in its Specialty & Primary Care saw revenues of €774.4 million with a growth of 2.6%. However, the Rare Diseases segment exhibited exceptional performance with a 29.2% revenue increase, attributed to robust demand across key franchises. This growth reflects the company's strategic focus on high-need areas.
Future Outlook and Fiscal Targets
Looking ahead, Recordati remains optimistic about achieving its fiscal year 2025 targets, anticipating net revenues between €2,600 and €2,670 million, EBITDA between €970 and €1,000 million, and adjusted net income in the range of €640 to €670 million. Despite the increased foreign exchange headwinds projected at about -3%, the company is positioned for growth across all metrics.
Strengthened Pipeline and Corporate Development
Moreover, Recordati's pipeline is advancing steadily with the recent approval for Isturisa (osilodrostat) for treating endogenous hypercortisolemia in adults. This reflects the company’s commitment to addressing unmet medical needs through innovative solutions.
Investment in Future Growth
Investments are being channeled into research and development to drive innovation in treatment options and expand therapeutic areas. This approach ensures that Recordati remains at the forefront of addressing health challenges.
Frequently Asked Questions
What drove Recordati's revenue growth in H1 2025?
Recordati's growth is attributed to strong sales in the Specialty & Primary Care and Rare Diseases sectors, alongside successful licensing agreements.
How did EBITDA perform in the first half of 2025?
The EBITDA reached €496.3 million, marking a 9.6% increase from the previous year.
What strategic partnerships has Recordati established recently?
Recordati entered a licensing and supply agreement with Amarin for the commercialization of Vazkepa across Europe.
What financial targets does Recordati aim to achieve for FY 2025?
Recordati aims for net revenues between €2,600 and €2,670 million and EBITDA between €970 and €1,000 million.
How does Recordati manage its debt levels?
Recordati maintains a balanced approach to debt management, reporting net debt at €2,127.1 million, which is just below 2.3x EBITDA pro-forma.
